Secretin effects on cerebellar-dependent motor learning in schizophrenia

Amanda R. Bolbecker, William P. Hetrick, Jason K. Johannesen, Brian O'Donnell, Joseph E. Steinmetz, Anantha Shekhar

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: Pervasive cognitive deficits in schizophrenia are a major cause of disability among individuals with the disorder. One such deficit is the loss of effective associative learning, which is readily assessed via eye-blink conditioning procedures. The authors examined the efficacy of secretin, a hormonal agonist for the prototype group B G-protein-coupled receptors, in ameliorating eye-blink conditioning deficits in schizophrenia patients. Method: Immediately following a pretreatment delay eye-blink conditioning recording session, 25 individuals with schizophrenia received either secretin (RG1068; 20 μg/kg [N=15]) or a saline placebo (20 μg/kg [N=10]) subcutaneously in a double-blind fashion. Comparison groups were formed by yoking pairs of subjects on the basis of performance during the pretreatment baseline eye-blink conditioning recording session, and thus 20 subjects underwent further analysis. Secretin was selected because eye-blink conditioning depends on the release of Purkinje cell inhibition on deep nuclei of the cerebellum and recent findings indicate that secretin is endogenously released in the cerebellum, where it acts as a retrograde messenger and neuromodulator on basket and Purkinje cells. Results: Eye-blink conditioning was significantly improved at 2 and 24 hours after secretin administration but not after treatment with placebo. These results are consistent with evidence of intracellular signaling abnormalities in the pathophysiology of schizophrenia and indicate a possible role for secretin in modulating cerebellar-mediated classically conditioned learning. Conclusion: If cerebellar abnormalities in individuals with schizophrenia are associated with fundamental mechanisms and symptoms of the disorder, as suggested by the cognitive dysmetria model, then cerebellar-targeted treatments may provide a novel approach to treatment for schizophrenia.

Original languageEnglish (US)
Pages (from-to)460-466
Number of pages7
JournalAmerican Journal of Psychiatry
Volume166
Issue number4
DOIs
StatePublished - Apr 2009
Externally publishedYes

Fingerprint

Secretin
Schizophrenia
Learning
Purkinje Cells
Cerebellum
Placebos
Cerebellar Ataxia
G-Protein-Coupled Receptors
Neurotransmitter Agents
Conditioning (Psychology)
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Secretin effects on cerebellar-dependent motor learning in schizophrenia. / Bolbecker, Amanda R.; Hetrick, William P.; Johannesen, Jason K.; O'Donnell, Brian; Steinmetz, Joseph E.; Shekhar, Anantha.

In: American Journal of Psychiatry, Vol. 166, No. 4, 04.2009, p. 460-466.

Research output: Contribution to journalArticle

Bolbecker, Amanda R. ; Hetrick, William P. ; Johannesen, Jason K. ; O'Donnell, Brian ; Steinmetz, Joseph E. ; Shekhar, Anantha. / Secretin effects on cerebellar-dependent motor learning in schizophrenia. In: American Journal of Psychiatry. 2009 ; Vol. 166, No. 4. pp. 460-466.
@article{7e40505039974d3da803b71d722521a6,
title = "Secretin effects on cerebellar-dependent motor learning in schizophrenia",
abstract = "Objective: Pervasive cognitive deficits in schizophrenia are a major cause of disability among individuals with the disorder. One such deficit is the loss of effective associative learning, which is readily assessed via eye-blink conditioning procedures. The authors examined the efficacy of secretin, a hormonal agonist for the prototype group B G-protein-coupled receptors, in ameliorating eye-blink conditioning deficits in schizophrenia patients. Method: Immediately following a pretreatment delay eye-blink conditioning recording session, 25 individuals with schizophrenia received either secretin (RG1068; 20 μg/kg [N=15]) or a saline placebo (20 μg/kg [N=10]) subcutaneously in a double-blind fashion. Comparison groups were formed by yoking pairs of subjects on the basis of performance during the pretreatment baseline eye-blink conditioning recording session, and thus 20 subjects underwent further analysis. Secretin was selected because eye-blink conditioning depends on the release of Purkinje cell inhibition on deep nuclei of the cerebellum and recent findings indicate that secretin is endogenously released in the cerebellum, where it acts as a retrograde messenger and neuromodulator on basket and Purkinje cells. Results: Eye-blink conditioning was significantly improved at 2 and 24 hours after secretin administration but not after treatment with placebo. These results are consistent with evidence of intracellular signaling abnormalities in the pathophysiology of schizophrenia and indicate a possible role for secretin in modulating cerebellar-mediated classically conditioned learning. Conclusion: If cerebellar abnormalities in individuals with schizophrenia are associated with fundamental mechanisms and symptoms of the disorder, as suggested by the cognitive dysmetria model, then cerebellar-targeted treatments may provide a novel approach to treatment for schizophrenia.",
author = "Bolbecker, {Amanda R.} and Hetrick, {William P.} and Johannesen, {Jason K.} and Brian O'Donnell and Steinmetz, {Joseph E.} and Anantha Shekhar",
year = "2009",
month = "4",
doi = "10.1176/appi.ajp.2008.08040597",
language = "English (US)",
volume = "166",
pages = "460--466",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "4",

}

TY - JOUR

T1 - Secretin effects on cerebellar-dependent motor learning in schizophrenia

AU - Bolbecker, Amanda R.

AU - Hetrick, William P.

AU - Johannesen, Jason K.

AU - O'Donnell, Brian

AU - Steinmetz, Joseph E.

AU - Shekhar, Anantha

PY - 2009/4

Y1 - 2009/4

N2 - Objective: Pervasive cognitive deficits in schizophrenia are a major cause of disability among individuals with the disorder. One such deficit is the loss of effective associative learning, which is readily assessed via eye-blink conditioning procedures. The authors examined the efficacy of secretin, a hormonal agonist for the prototype group B G-protein-coupled receptors, in ameliorating eye-blink conditioning deficits in schizophrenia patients. Method: Immediately following a pretreatment delay eye-blink conditioning recording session, 25 individuals with schizophrenia received either secretin (RG1068; 20 μg/kg [N=15]) or a saline placebo (20 μg/kg [N=10]) subcutaneously in a double-blind fashion. Comparison groups were formed by yoking pairs of subjects on the basis of performance during the pretreatment baseline eye-blink conditioning recording session, and thus 20 subjects underwent further analysis. Secretin was selected because eye-blink conditioning depends on the release of Purkinje cell inhibition on deep nuclei of the cerebellum and recent findings indicate that secretin is endogenously released in the cerebellum, where it acts as a retrograde messenger and neuromodulator on basket and Purkinje cells. Results: Eye-blink conditioning was significantly improved at 2 and 24 hours after secretin administration but not after treatment with placebo. These results are consistent with evidence of intracellular signaling abnormalities in the pathophysiology of schizophrenia and indicate a possible role for secretin in modulating cerebellar-mediated classically conditioned learning. Conclusion: If cerebellar abnormalities in individuals with schizophrenia are associated with fundamental mechanisms and symptoms of the disorder, as suggested by the cognitive dysmetria model, then cerebellar-targeted treatments may provide a novel approach to treatment for schizophrenia.

AB - Objective: Pervasive cognitive deficits in schizophrenia are a major cause of disability among individuals with the disorder. One such deficit is the loss of effective associative learning, which is readily assessed via eye-blink conditioning procedures. The authors examined the efficacy of secretin, a hormonal agonist for the prototype group B G-protein-coupled receptors, in ameliorating eye-blink conditioning deficits in schizophrenia patients. Method: Immediately following a pretreatment delay eye-blink conditioning recording session, 25 individuals with schizophrenia received either secretin (RG1068; 20 μg/kg [N=15]) or a saline placebo (20 μg/kg [N=10]) subcutaneously in a double-blind fashion. Comparison groups were formed by yoking pairs of subjects on the basis of performance during the pretreatment baseline eye-blink conditioning recording session, and thus 20 subjects underwent further analysis. Secretin was selected because eye-blink conditioning depends on the release of Purkinje cell inhibition on deep nuclei of the cerebellum and recent findings indicate that secretin is endogenously released in the cerebellum, where it acts as a retrograde messenger and neuromodulator on basket and Purkinje cells. Results: Eye-blink conditioning was significantly improved at 2 and 24 hours after secretin administration but not after treatment with placebo. These results are consistent with evidence of intracellular signaling abnormalities in the pathophysiology of schizophrenia and indicate a possible role for secretin in modulating cerebellar-mediated classically conditioned learning. Conclusion: If cerebellar abnormalities in individuals with schizophrenia are associated with fundamental mechanisms and symptoms of the disorder, as suggested by the cognitive dysmetria model, then cerebellar-targeted treatments may provide a novel approach to treatment for schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=64949104277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64949104277&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2008.08040597

DO - 10.1176/appi.ajp.2008.08040597

M3 - Article

VL - 166

SP - 460

EP - 466

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 4

ER -